Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 14, Issue 3, Pages 429-437
Publisher
Informa Healthcare
Online
2015-01-02
DOI
10.1517/14740338.2015.998198
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AB0520 Tocilizumab in rheumatoid arthritis – one year interim analysis of the non-interventional ichiban study:
- (2014) C. Specker et al. ANNALS OF THE RHEUMATIC DISEASES
- FRI0323 Prospective Follow-Up of Tocilizumab Treatment in 1503 Patients with Refractory Rheumatoid Arthritis: Tolerance Data at 1 Year from the French Registry Regate (Registry – Roactemra)
- (2014) J. Morel et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2014) Jackie L Nam et al. ANNALS OF THE RHEUMATIC DISEASES
- The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
- (2014) Marita Cross et al. ANNALS OF THE RHEUMATIC DISEASES
- What is the future of targeted therapy in rheumatology: biologics or small molecules?
- (2014) Attila Mócsai et al. BMC Medicine
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
- (2014) Norihiro Nishimoto et al. Modern Rheumatology
- The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis
- (2014) Anshuman P. Malaviya et al. RHEUMATOLOGY
- Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
- (2014) Alan Kivitz et al. ARTHRITIS CARE & RESEARCH
- The Biology and Medical Implications of Interleukin-6
- (2014) T. Tanaka et al. Cancer Immunology Research
- A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
- (2013) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
- (2013) Joachim Listing et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Work disability and state benefit claims in early rheumatoid arthritis: the ERAN cohort
- (2013) D. F. McWilliams et al. RHEUMATOLOGY
- Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
- (2013) Atsushi Ogata et al. ARTHRITIS CARE & RESEARCH
- Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor
- (2012) Iris Navarro-Millán et al. CLINICAL THERAPEUTICS
- The role of tocilizumab in the management of rheumatoid arthritis
- (2012) Zoe Ash et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)
- (2011) Jeffrey Kaine et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
- (2011) H. C. Leffers et al. ANNALS OF THE RHEUMATIC DISEASES
- Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries
- (2010) X. Mariette et al. RHEUMATOLOGY
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry
- (2008) M L Hetland et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- The development of novel therapies for rheumatoid arthritis
- (2008) Ling-dong Quan et al. EXPERT OPINION ON THERAPEUTIC PATENTS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now